Sensei Biotherapeutics SNSE 深 沪
已收盘 11-14 16:00:00 美东时间
8.005
-1.015
-11.25%
华盛通- 最 高9.4985
- 今 开9.46
- 成交量 2.30万股
- 最 低 7.59
- 昨 收 9.02
- 总市值 1009.67万
- 52周最高 18.35
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.00
- 委 比 12.28%
- 总股本 126.13万
- 历史最高 530.00
- 量 比 0.77
- 振 幅 21.16%
- 历史最低 5.00
- 每 手 1
- 风险率 1.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sensei Biotherapeutics GAAP EPS of -$3.62
Sensei Biotherapeutics press release (SNSE): Q3 GAAP EPS of -$3.62. Cash, cash equivalents and marketable securities were $25.0 million as of September 30, 2025, as compared to $41.3 million as of Dec...
11-14 20:46
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
Sensei Biotherapeutics reported Q3 2025 financial results, announcing the discontinuation of solnerstotug development and initiating a strategic review to maximize shareholder value. The company reduced its workforce by 65% to preserve cash. Financial highlights include $25.0 million in cash, reduced R&D expenses to $2.5 million, G&A expenses at $2.3 million, and a net loss of $4.6 million. Key financial metrics reflect cost reductions and ongoin...
11-14 12:30
HC Wainwright & Co. Downgrades Sensei Biotherapeutics to Neutral
HC Wainwright & Co. analyst Matthew Keller downgrades Sensei Biotherapeutics (NASDAQ:SNSE) from Buy to Neutral.
10-31 00:27
Sensei Biotherapeutics Board Determines To Discontinue Development Of Solnerstotug And Initiate Comprehensive Review Of Strategic Alternatives To Maximize Shareholder Value
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Board of Directors
10-30 21:10
Sensei Biotherapeutics Releases Results From The Phase 1/2 Dose Expansion Study Of Solnerstotug Presented At ESMO 2025. The Data Addressed The Critical Challenge Of Secondary Resistance To Immune Checkpoint Inhibitors, Where Treatment Success Rates Are Typically Below 5%
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced results from the dose
10-17 20:16
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
Sensei Biotherapeutics announced promising results from the dose expansion portion of its Phase 1/2 trial for solnerstotug, a VISTA-targeting monoclonal antibody. The 15 mg/kg dose showed a 6-month progression-free survival (PFS) of 50% in PD-(L)1 refractory patients, with all clinical responses, including a complete response, occurring in this cohort. The safety profile was favorable, with only mild cytokine release syndrome (CRS) events reporte...
10-17 12:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 32.1% to...
10-09 05:06
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
Sensei Biotherapeutics will host a virtual KOL event on October 20, 2025, featuring discussions on immunotherapy-resistant solid tumors, updates on Phase 2 studies, and data from Phase 1/2 trials of solnerstotug, a VISTA-targeting antibody. The event will include a Q&A session. Sensei's TMAb platform develops therapeutics to target the tumor microenvironment, with solnerstotug selectively blocking VISTA in low pH conditions to activate T cells ag...
09-23 11:30
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
<p>Sensei Biotherapeutics announced that John Celebi, its CEO, will participate in 1x1 investor meetings at the H.C. Wainwright Global Investment Conference on September 8, 2025. An on-demand corporate presentation will be available on the company's website starting September 5, 2025, and a webcast replay will be accessible for 90 days. The company focuses on developing next-generation cancer therapeutics using its TMAb platform, with its lead ca...
09-03 12:00
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics reported Q2 2025 financial results and provided updates on its clinical program for solnerstotug. The company highlighted the completion of enrollment in its Phase 1/2 trial with 64 patients, including those with PD-(L)1 resistant tumors. Solnerstotug demonstrated favorable safety profiles and efficacy signals, with full dose expansion data expected by year-end 2025. The company also mentioned plans for multiple Phase 2 stu...
08-05 11:30
